Complete Remission to Afatinib in a Patient Harboring a Novel Epidermal Growth Factor Mutation in De Novo Small-Cell Lung Cancer: A Case Report: Clinical Lung Cancer

Clin Lung Cancer. 2022 Jun;23(4):e289-e292. doi: 10.1016/j.cllc.2021.11.002. Epub 2021 Nov 10.

¹ Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria. Electronic address: maximilian.hochmair@gesundheitsverbund.at.
² Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria.
³ Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
⁴ Department of Pathology and Bacteriology, Klinik Floridsdorf, Vienna, Austria.

No abstract available

Keywords: ED-SCLC; EGFR inhibitor; Exon 18-point mutation; Patient who never smoked; Targeted therapy.

Publication types